Status:
WITHDRAWN
The Role of the Noradrenergic System in the Nonmotor Symptoms of Parkinson's Disease
Lead Sponsor:
Nathaniel M. Robbins
Conditions:
Parkinson Disease
Eligibility:
All Genders
Phase:
EARLY_PHASE1
Brief Summary
The goal of this clinical trial is to learn about the role of noradrenergic system in the non-motor symptoms of Parkinson's disease. The main objectives it aims to answer are: 1. To explore the assoc...
Detailed Description
This is a cross-sectional pilot study comparing 10 PD patients with Orthostatic hypertension (OH) to 10 PD patients without OH. OH is defined as a drop in blood pressure within 5 minutes of standing (...
Eligibility Criteria
Inclusion
- Participant able to provide informed consent
- Diagnosis of Parkinson's disease confirmed by a DH neurologist according to Movement Disorder Society criteria, with the exception that "Red flag" 5a will not be used (severe autonomic failure within five years of disease onset).
- All subjects must have CMP and CBC drawn within 6 months of study visit 1, with results in the normal range or with abnormal results not considered to be clinically significant in the investigator's opinion.
- Female patients must be post-menopausal (at least one year) or not planning to get pregnant and have negative pregnancy test.
Exclusion
- Diagnosis or previous history of diabetes of any kind
- Known autonomic neuropathy unrelated to PD
- History of or current cardiac, liver or renal disease that, in the opinion of the investigator, may put the patient at risk because of participation in the study
- Known condition that in the investigator's opinion would be a contraindication to HUT testing or yohimbine challenge (e.g. decompensated cardiac disease, severe positional vertigo; severe anxiety, known panic disorder69)
- Current use of catecholaminergic medications (e.g. stimulants, droxidopa, midodrine) that cannot be held for at least three half-lives
- Inability to hold PD medications for at least 12 hours
- History of major depressive or bipolar disorder preceding the diagnosis of PD,69 or diagnosis or previous history of psychiatric illness that in the investigator's opinion would affect the subject's ability to successfully participate in the study.
- Any history (other than PD) that could significantly and adversely affect neurocognitive function, such as history of traumatic brain injury (head injury with loss of consciousness \> 1 hour), known dementia unrelated to Parkinson's or related diseases; developmental delay, multiple sclerosis or epilepsy with cognitive impairment, intellectual deficit, diagnosed and untreated sleep apnea; untreated syphilis; HIV with HAND; or other conditions that, based on the investigators opinion, could interfere with neurocognitive evaluation.
- Known ophthalmologic disease such as untreated cataract, glaucoma, optic neuritis, orbital trauma, or other neuroretinal disease that might impact pupillary function
- Severe illness within 30 days prior to enrollment.
- Use of opiate, procholinergic, or other medications influencing pupillary function that cannot be held for three half-lives
- In the Investigator's opinion, subject would be unable to successfully participate in the study for any reason.
Key Trial Info
Start Date :
May 11 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04346394
Start Date
May 11 2021
End Date
August 1 2023
Last Update
August 23 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dartmouth-Hitchcock
Lebanon, New Hampshire, United States, 03756